SQZ SQZ Biotechnologies Company

12.28
-0.98  -7%
Previous Close 13.26
Open 13
52 Week Low 11.15
52 Week High 35.17
Market Cap $344,660,243
Shares 28,066,795
Float 21,223,215
Enterprise Value $279,469,701
Volume 34,068
Av. Daily Volume 61,043
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SQZ-PBMC-HPV-101
Solid Tumors
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

    PRESENTATION DETAILS

    Wednesday, November 17
    Stifel 2021 Virtual Healthcare Conference
    10:00 am ET
    Webcast

    Specific conference webcast details and the company's corporate overview presentation will be available on the Investors & Media section of the SQZ website. The webcast will be available for 90 days following the presentation.

    About SQZ Biotechnologies
    SQZ Biotechnologies…

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

    PRESENTATION DETAILS

    Wednesday, November 17

    Stifel 2021 Virtual Healthcare Conference

    10:00 am ET

    Webcast

    Specific conference webcast details and the company's corporate overview presentation will be available on the Investors & Media section of the SQZ website. The webcast will be available for 90 days following the presentation.

    About SQZ Biotechnologies

    SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

    View Full Article Hide Full Article
  2. SQZ™ AACs Demonstrate Synergistic Effects with Chemotherapy in HPV16+ Cancer Model

    SQZ™ eAPCs Engineered with Multiple mRNAs Drive Robust CD8+ T Cell Response and are Potentially Applicable to Broader HPV16+ Cancer Patient Population

    mRNA Engineered TILs Show Potency without Additional IL-2 Support in Melanoma Model

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy. The company also presented new research on the development of enhanced tumor infiltrating lymphocytes…

    SQZ™ AACs Demonstrate Synergistic Effects with Chemotherapy in HPV16+ Cancer Model

    SQZ™ eAPCs Engineered with Multiple mRNAs Drive Robust CD8+ T Cell Response and are Potentially Applicable to Broader HPV16+ Cancer Patient Population

    mRNA Engineered TILs Show Potency without Additional IL-2 Support in Melanoma Model

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy. The company also presented new research on the development of enhanced tumor infiltrating lymphocytes (TILs) that show increased potency in the absence of exogenous cytokine (IL-2) support. The data was presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C. and virtually.

    "Our presentations at SITC provide compelling new preclinical data on the multiple biologically diverse, directed immunity approaches that we are pursuing for cancer therapies," said Howard Bernstein, M.D., Ph.D., Chief Scientific Officer at SQZ Biotechnologies. "Our AAC and eAPC platform work provides translational insights that are relevant to clinical development, including combination chemotherapy and potential expansion to broader patient populations and tumor types."

    "We are also excited to present initial preclinical results on enhanced tumor infiltrating lymphocytes, highlighting a potential future therapeutic avenue," said Jonathan Gilbert, Ph.D., Vice President and Head of Exploratory Research, SQZ Biotechnologies. "Working with tumor reactive TILs provided by AgonOx, Inc., we developed mRNA engineered TILs that can proliferate and kill matched patient tumor cells in the absence of exogenous IL-2 cytokine support. Engineered TILs may enable the removal of toxic preconditioning and systemic IL-2 use with TIL therapies, making them more broadly applicable to patients."

    Major Findings from Preclinical Research

    Poster #156: RBC-Derived, Activating Antigen Carriers (SQZ™ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo

    • SQZ Activating Antigen Carriers (AAC) were derived from red blood cells (RBCs) and engineered to direct tumor-specific antigens and adjuvant to endogenous professional APCs, which subsequently activated T cell responses in vivo
    • In TC-1 tumor bearing mice, a model of HPV16+ cancers, AACs demonstrated a synergistic therapeutic effect in combination with cisplatin, a common chemotherapy used in many clinical settings
    • Median survival of mice increased in all combination treatment cohorts compared to single agent cisplatin or ACC treatment

    Poster #211: SQZ™ eAPCs Generated from PBMCs by Delivery of Multiple mRNAs Encoding for Antigens, Costimulatory Proteins, and Engineered Cytokines

    • SQZ Enhanced Antigen Presenting Cells (eAPC) derived from peripheral blood mononuclear cells (PBMCs) and engineered with various mRNA encoding for multiple target antigens and immuno-stimulation signals, including CD86 and membrane bound IL-2 and IL-12, generated robust T cell responses in human in-vitro models
    • HPV16-encoding mRNA delivery to PBMCs stimulated CD8+ T cells across a range of HLA haplotypes, supporting future eAPC clinical development in broad HPV16+ patient populations
    • eAPC data highlights the potential to expand the therapeutic impact across tumor types by changing the antigen-encoding mRNA

    Poster #165: Generating Enhanced Tumor Infiltrating Lymphocytes through Microfluidic Cell Squeezing

    • Cell Squeeze® delivery of mRNA encoding membrane bound IL-2 (mbIL2) and IL-12 (mbIL12) into expanded tumor reactive CD8 human tumor infiltrating lymphocytes (TILs) from AgonOx* (AGX-148) demonstrated high levels of membrane-bound cytokine expression in vitro
    • Enhanced TILs proliferated independent of exogenous IL-2 and demonstrated improved granzyme B levels, illustrating the potential to eliminate systemic IL-2 administration in the clinical setting.
    • In an in vitro co-culture model with matched human melanoma cells, enhanced TILs demonstrated increased tumor killing as compared to un-modified TILs

    * AgonOx, Inc. is a biotechnology company with a close alignment with the Earle A. Chiles Research Institute at the Providence Cancer Institute in Portland, OR.

    About SQZ Biotechnologies

    SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our platform development, manufacturing capabilities, product candidates, preclinical and clinical activities, outcomes and progress, development plans and execution, clinical efficacy, therapeutic impact, and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

    Certain information contained in this press release relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy, or completeness of any information obtained from third-party sources.

    View Full Article Hide Full Article
    • Highest Dose Monotherapy Data from Phase 1/2 Trial of SQZ-PBMC-HPV-101 Accepted for Oral Presentation at ESMO IO
    • SQZ-PBMC-HPV-101 Advances into Combination with Checkpoint Inhibitors
    • eAPC IND Submission Anticipated by Year-End 2021
    • Celiac Disease TAC Platform IND Submission Anticipated by Q3 2022

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2021 financial results and recent portfolio updates.

    "This was another period of strong execution where we have continued to meaningfully advance our cell therapy platforms and clinical programs. We were pleased with the recent DSMB recommendation to advance our highest APC dose into combination…

    • Highest Dose Monotherapy Data from Phase 1/2 Trial of SQZ-PBMC-HPV-101 Accepted for Oral Presentation at ESMO IO
    • SQZ-PBMC-HPV-101 Advances into Combination with Checkpoint Inhibitors
    • eAPC IND Submission Anticipated by Year-End 2021
    • Celiac Disease TAC Platform IND Submission Anticipated by Q3 2022

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2021 financial results and recent portfolio updates.

    "This was another period of strong execution where we have continued to meaningfully advance our cell therapy platforms and clinical programs. We were pleased with the recent DSMB recommendation to advance our highest APC dose into combination with checkpoint inhibitors for patients with HPV16 positive cancers," said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. "We were also excited to announce that celiac disease will be the first autoimmune disease target for our TAC platform, with an IND submission projected for next year. These activities highlight our deep commitment to driving patient impact across disease areas through the implementation of innovative cell therapies."

    Third Quarter 2021 and Recent Business and Portfolio Updates

    SQZ™ Antigen Presenting Cell ("APC") Platform in Oncology

    • Independent Data and Safety Monitoring Board (DSMB) recommends that the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 advance into the combination stage with checkpoint inhibitors
    • DSMB recommendation and initiation of the combination cohorts trigger Roche collaboration agreement milestone payment
    • Oral presentation on highest-dose cohort of SQZ-PBMC-HPV-101 trial announced for the ESMO Immuno-Oncology Congress, December 9, 2021 in Geneva, Switzerland

    SQZ™ Enhanced Antigen Presenting Cell ("eAPC") Platform in Oncology

    • New eAPC preclinical data to be presented on November 12, 2021 at the Society for Immunotherapy of Cancer (SITC) Congress demonstrates delivery of multiple mRNA to engineer APC function
    • Anticipate IND submission for the first clinical candidate by year-end 2021

    SQZ™ Activating Antigen Carriers ("AAC") Platform in Oncology

    • New AAC preclinical data to be presented at SITC highlights the potential combination therapy impact of SQZ AACs with a chemotherapy agent often used in early-line treatment of HPV16+ cancers

    SQZ™ Tolerizing Antigen Carriers ("TAC") Platform in Immune Tolerance

    • Announced Q3 2022 IND submission target for celiac disease as the first clinical translation of the company's TAC platform in autoimmune diseases

    SQZ™ Potential Pipeline Expansion Research

    • Presenting first enhanced tumor infiltrating lymphocyte (TIL) preclinical data at SITC showing the development of mRNA modified TILs with enhanced functionality in the absence of exogenous IL-2 cytokine support

    Third Quarter 2021 Financial Highlights

    • Revenue for the third quarter 2021 was $4.8 million, compared to $6.1 million for the same period last year
    • Net loss for the third quarter 2021 was $22.5 million, compared to $12.4 million for the same period last year
    • Research and development expenses for the third quarter 2021 were $20.5 million, compared to $13.9 million for the same period last year. The increase was primarily attributable to planned development and manufacturing costs related to the eAPC platform
    • General and administrative expenses for the third quarter 2021 were $6.7 million, compared to $4.6 million for the same period last year. The increase was primarily due to higher personnel and other corporate-related costs, including stock-based compensation expense and other costs related to operating as a public company
    • As of September 30, 2021, the company had cash and cash equivalents of $164.3 million and anticipates this will be sufficient to fund operating expenses and capital expenditure requirements through the first half of 2023. This projected cash runway is inclusive of the anticipated Roche milestone payment associated with the advancement of the SQZ-PBMC-HPV-101 Phase 1/2 study

    About SQZ Biotechnologies

    SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our financial condition and cash position, platform development, manufacturing capabilities, product candidates, preclinical and clinical activities, outcomes and progress, development plans and execution, clinical efficacy, regulatory submissions, therapeutic impact, upcoming events and presentations, and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

    Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

    SQZ BIOTECHNOLOGIES COMPANY

    Condensed Consolidated Statements of Operations

    (In thousands, except share and per share amounts)

    (unaudited)

     

     

    THREE MONTHS ENDED

    SEPTEMBER 30,

     

     

    NINE MONTHS ENDED

    SEPTEMBER 30,

     

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

    Collaboration revenue

     

    $

    4,755

     

     

    $

    6,121

     

     

    $

    14,748

     

     

    $

    18,511

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    20,520

     

     

     

    13,910

     

     

     

    52,942

     

     

     

    37,815

    General and administrative

     

     

    6,691

     

     

     

    4,612

     

     

     

    18,744

     

     

     

    14,139

    Operating expenses

     

     

    27,211

     

     

     

    18,522

     

     

     

    71,686

     

     

     

    51,954

    Loss from operations

     

     

    (22,456

    )

     

     

    (12,401

    )

     

     

    (56,938

    )

     

     

    (33,443)

    Other income, net

     

     

    6

     

     

     

    50

     

     

     

    19

     

     

     

    523

    Net loss

     

     

    (22,450

    )

     

     

    (12,351

    )

     

     

    (56,919

    )

     

     

    (32,920)

    Net loss per share attributable to common stockholders, basic and diluted

     

    $

    (0.80

    )

     

    $

    (7.03

    )

     

    $

    (2.08

    )

     

    $

    (18.87)

    Weighted-average common shares outstanding, basic and diluted

     

     

    28,050,130

     

     

     

    1,758,039

     

     

     

    27,421,839

     

     

     

    1,744,948

     

    SQZ BIOTECHNOLOGIES COMPANY

    Condensed Consolidated Balance Sheets

    (In thousands)

    (unaudited)

     

     

    SEPTEMBER 30,

    2021

     

     

    DECEMBER 31,

    2020

    Assets

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    164,254

     

     

    $

    170,357

    Other current assets

     

     

    1,913

     

     

     

    6,474

    Total current assets

     

     

    166,167

     

     

     

    176,831

    Other assets

     

     

    77,906

     

     

     

    54,310

    Total assets

     

    $

    244,073

     

     

    $

    231,141

    Liabilities and Stockholders' Equity

     

     

     

     

     

     

     

    Current liabilities

     

     

    39,109

     

     

     

    45,193

    Long term liabilities

     

     

    71,758

     

     

     

    58,749

    Total liabilities

     

     

    110,867

     

     

     

    103,942

    Total stockholders' equity

     

     

    133,206

     

     

     

    127,199

    Total liabilities and stockholders' equity

     

    $

    244,073

     

     

    $

    231,141

     

    View Full Article Hide Full Article
  3. High Dose Monotherapy Cohort Clinical Data from the SQZ-PBMC-HPV-101 Trial Accepted for Oral Presentation at ESMO IO in December

    Cohorts in Combination with anti-PD-(L)1 and anti-CTLA-4 Open for Enrollment

    Combination Stage Initiation Triggers Milestone Payment from Roche

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 has recommended that the trial advance into the combination stage with checkpoint inhibitors. In June, the company presented initial results from the first three monotherapy cohorts at the American Society of Clinical Oncology…

    High Dose Monotherapy Cohort Clinical Data from the SQZ-PBMC-HPV-101 Trial Accepted for Oral Presentation at ESMO IO in December

    Cohorts in Combination with anti-PD-(L)1 and anti-CTLA-4 Open for Enrollment

    Combination Stage Initiation Triggers Milestone Payment from Roche

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 has recommended that the trial advance into the combination stage with checkpoint inhibitors. In June, the company presented initial results from the first three monotherapy cohorts at the American Society of Clinical Oncology annual meeting demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic human papillomavirus positive (HPV16+) tumors. Data from the highest dose monotherapy cohort has been accepted for oral presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress being held December 8-11, 2021.

    "We are encouraged by our initial SQZ-PBMC-HPV-101 Phase 1/2 trial data and pleased to advance the highest dose of our SQZ APC clinical candidate into the combination stage of the trial," said Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies. "Based on our preclinical studies and available clinical trial data, we believe SQZ APCs could work synergistically with checkpoint inhibitors to provide additional clinical benefit to patients. Our clinical team and trial sites are ready to begin this important phase of the study."

    The combination stage of the trial is now open for enrollment and will include checkpoint inhibitors targeting the PD-(L)1 and CTLA-4 pathways. In parallel, the company plans to continue to enroll in the highest dose monotherapy cohort.

    The DSMB recommendation and initiation of the combination cohorts will trigger a Roche collaboration agreement milestone payment. The company's most recently reported cash runway projections anticipated these proceeds.

    New data from the monotherapy portion of the SQZ-PBMC-HPV-101 trial will be part of an oral presentation at ESMO-IO on December 9 in Geneva, Switzerland. Full presentation details can be found below.

    ESMO-IO Presentation Details

    • Oral Presentation: Thursday, December 9 at 12:10 pm CET
    • Presentation Number: 48MO

    Abstract Title: SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA-A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors

    Lead Author: Jong Chul Park, MD, Massachusetts General Hospital; Developmental Therapeutics Member, Dana-Farber/Harvard Cancer Center

    ESMO-IO will publish full abstracts on their website on Thursday, December 2 at 12:00 pm CET. SQZ will post its oral presentation on the company website on December 9 at 11:00 am CET.

    SQZ-PBMC-HPV-101 Trial Design

    SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors. Patients must be positive for the human leukocyte antigen serotype HLA-A*02. The investigational candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination with immuno-oncology agents. The study's primary outcome measures in the monotherapy and combination phases of the trial include safety and tolerability. Antitumor activity is a secondary outcome measure in both the monotherapy and combination stages of the trial, and manufacturing feasibility is a secondary outcome measure in the monotherapy phase of the trial. The monotherapy phase of the study includes escalating dose cohorts with a dose-limiting toxicity (DLT) window of 28 days and the definition of a recommended phase 2 dose. The planned combination phase of the study will include SQZ-PBMC-HPV and checkpoint inhibitors. DLT will be measured over 42 days.

    About Human Papillomavirus Positive Cancers

    Human papillomavirus (HPV) is one of the most common viruses worldwide and certain strains persist for many years leading to cancer. According to the Centers for Disease Control (CDC), in the United States HPV+ tumors represent 3% of all cancers in women and 2% of all cancers in men, resulting in over 39,000 new cases of HPV+ tumors every year. HPV infection is larger outside of the U.S., and according to the International Journal of Cancer HPV+ tumors account for 4.5% of all cancers worldwide, resulting in approximately 630,000 new cases every year. According to the CDC, HPV infection plays a significant role in the formation of more than 90% of anal and cervical cancers, and most cases of vaginal (75%), oropharyngeal (70%), vulval (70%) and penile (60%) cancers.

    About SQZ Biotechnologies

    SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our platform development, manufacturing capabilities, product candidates, preclinical and clinical activities, progress and outcomes, development plans, clinical efficacy, therapeutic impact, strategic partnerships and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors and strategic partners; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

    Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

    View Full Article Hide Full Article
  4. Posters Detail Preclinical Data on SQZ AAC and eAPC Platforms and Enhanced Tumor Infiltrating Lymphocytes

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. The data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

    "We are excited to share new preclinical data on our AAC and eAPC platforms, as well as initial data on the engineering of tumor infiltrating lymphocytes," said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. "These…

    Posters Detail Preclinical Data on SQZ AAC and eAPC Platforms and Enhanced Tumor Infiltrating Lymphocytes

    SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. The data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

    "We are excited to share new preclinical data on our AAC and eAPC platforms, as well as initial data on the engineering of tumor infiltrating lymphocytes," said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. "These data further highlight our potential to create multiple cell therapies leveraging diverse biology to combat cancer."

    POSTER PRESENTATIONS

    Title: RBC-Derived, Activating Antigen Carriers (SQZ™ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo

    Presenter: Katarina Blagovic, PhD

    Abstract Number: 156

    Title: Generating Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic Cell Squeezing

    Presenter: Devin Bridgen, PhD

    Abstract Number: 165

    Title: SQZ™ eAPCs Generated from PBMCs by Delivery of Multiple mRNAs Encoding for Antigens, Costimulatory Proteins, and Engineered Cytokines

    Presenter: Michael F. Maloney, PhD

    Abstract Number: 211

    Full text of the abstracts will be available on the SITC website at 8:00 a.m. ET on Tuesday, November 9, and posters will be available on the company's website at 7:00 a.m. ET on November 12. Live poster presentations will be on November 12 and 13 from 7:00 a.m. - 8:30 p.m. ET.

    About SQZ Biotechnologies

    SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our platform development, manufacturing capabilities, product candidates, preclinical and clinical activities and outcomes, development plans and progress, clinical efficacy, therapeutic impact and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

    Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

    View Full Article Hide Full Article
View All SQZ Biotechnologies Company News